Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Men experience and express depression differently, often coping through unhealthy behaviors and resisting treatment due to ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according t ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...